Astragaloside IV protects cardiomyocytes against hypoxia injury via and the pathway.

BACKGROUND

Hypoxia is an important cause of myocardial injury due to the heart's high susceptibility to hypoxia. Astragaloside IV (AS-IV) is the main component of and could exert cardiac protective role. Here, the effect of AS-IV on hypoxia-injured H9c2 cardiomyocytes was elucidated.

METHODS

First, H9c2 cells were exposed to hypoxia and/or AS-IV treatment. Cell apoptosis, death, and viability as well as () expression and apoptotic proteins were analyzed. Next, transfection of si- into H9c2 cells was carried out to test whether upregulation and stabilization of influences the effect of AS-IV on hypoxia-treated H9c2 cells. Furthermore, the regulatory role of () signaling on levels was examined.

RESULTS

Hypoxia suppressed viability and promoted the apoptosis and death of H9c2 cells. AS-IV eliminated hypoxia-induced H9c2 injury. Moreover, signaling was further activated and stabilized by AS-IV in hypoxia-challenged H9c2 cells. Downregulation of suppressed the function of AS-IV in hypoxia-challenged H9c2 cells. AS-IV promoted signaling in hypoxia-induced injury. The beneficial functions of AS-IV in hypoxia-exposed H9c2 cells were linked to upregulation and signaling activation.

CONCLUSIONS

AS-IV relieved H9c2 cardiomyocyte injury after hypoxia, possibly by activating -mediated signaling.